9 results
The primary objective is to examine whether a memory impairment as a result of biperiden treatment (cholinergic M1 antagonist) will be increased by acute tryptophan depletion (ATD, a drink that decreases serotonin synthesis). In other words, we will…
The primary objective is to examine whether a memory impairment as a result of biperiden treatment (cholinergic M1 antagonist) can be reversed by rivastigmine (a cholinesterase inhibitor). Secondary, we will assess the effects of biperiden and…
Primary- To evaluate the safety and tolerability of long-term intermittent use of lasmiditan for the acute treatment of migraine in pediatric patients.Key Secondary- To evaluate the efficacy of intermittently dosed lasmiditan in the treatment of…
Primary: - To evaluate the efficacy of 2 dose quantities of lasmiditan on migraine headache pain freedom compared to placebo - To evaluate the consistency of response to 2 dose quantities of lasmiditan compared to placeboSecondary: - To evaluate the…
• To determine the profile of CNS effects at several time points after 2 mg and 4 mg biperiden in comparison to placebo in healthy elderly subjects.• To investigate the safety and tolerability of biperiden in healthy elderly subjects.• To determine…
We will examine the cognitive performance of healthy young participants at different time points after a single administration of biperiden. The behavioural outcomes and electrophysiological correlates will be linked with the serum levels of…
The main objective of the study is to investigate whether ciprofibrate treatment can improve myocardial insulin sensitivity in subjects with IGM. As secondary objectives we want to investigate whether ciprofibrate treatment also improves diastolic…
- Characterization of the CNS PD profile of IV administered biperiden- Characterization of the pharmacokinetic profile of IV administered biperiden- To confirm the plasma concentration-effect relationship of biperiden using population PK-PD modeling…
Primary- To test the hypothesis that lasmiditan high dose is superior to placebo in the acute treatment of a migraine attack in pediatric patients >=6 to <18 years of ageKey Secondary- To test the hypothesis that lasmiditan medium dose…